Bio Sequence

Expand your analysis with a 360° industry overview!

16 January 2024
3 min read

Patsnap Bio Sequence Database has enhanced the analysis page to include sequence and literature reports now! 

Gain instant access to industry insights for your sequence of interest with exportable reports summarizing length and identity distribution, drug and patent activity, IP and literature trends, and more!

The following example uses Semaglutide sequence retrieval to illustrate data transformation from the logical form of search results into the visual form of images. Let's take a closer look at these image effects!

Detailed operation steps:

At the homepage of Patsnap Bio Sequence Database, input the sequence of Semaglutide in the regular search: HVEGTFTSDV SSYLEGQAAK EEIAWLVKGR G, click on the search to get its similar sequence data results (including sequence data, patent data, literature data, data from other libraries, and analysis view).

图形用户界面, 应用程序

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Overview

In the analysis view, the Venn diagram in the overview displays the number of sequences cross-referenced from various sequence sources. 4087 sequences are published in patents, 264 sequences are published in papers, and 4424 sequences are published in other sources, of which 110 sequences are published in patents, papers, and other sources.

图示

描述已自动生成

Sequence Analysis

In the analysis view, several aspects of the sequence results are visualized, including the overall distribution of sequence lengths, the overall distribution of alignment identity, the overall distribution of query Identity, the top ten drugs based on sequences, and the top ten genes based on sequences.

图表, 折线图

描述已自动生成

From the analysis view, we can easily see the top 10 drugs corresponding to the Semaglutide sequence retrieval results.

图形用户界面, 应用程序, 表格, Excel

描述已自动生成

Patent Analysis

In the analysis view, the patents of the sequence search results are also clearly visualized, including the column chart of the patent application and grant trends in the past ten years, the pie chart of the simple legal status distribution of the selected patents, the main countries/regions of the technology layout, the key of the top 10 applicants among the selected patents, and the top 10 competitive landscape over time.

图形用户界面, 应用程序

描述已自动生成

Literature Analysis

In the analysis view, statistical analyses of the literature results of sequence retrieval are conducted, including the distribution of literature publication years, the top 10 literature publishing journals, and the top 10 literature publishing institutions.

The number of publicly available literature on Semaglutide peptide sequence retrieval rapidly increased from 2008 to 2015 and then remained steady, reaching another peak in 2021. The journal Diabetes, Obesity, and Metabolism ranked first in literature publishing, while the University of Copenhagen ranked first in literature publishing institutions. For more detailed data, refer to the figure below and log in to the Patsnap Bio database.

图表

描述已自动生成

图表, 漏斗图

描述已自动生成

It is important to note that Patsnap Bio is the most extensive sequence search platform for the Patsnap database. It incorporates AI with human-curated data for comprehensive handling of protein and nucleotide sequence data plucked from global patents, biological periodicals, and public repositories. Essential biological sequences are manually annotated, illuminating structural modifications to provide the most accurate sequence data and boost sequence retrieval efficiency.

Free registration is available for the Bio biological sequence database: https://bio.patsnap.com. Act now to expedite your sequence search tasks.

FDA Fast-Tracks Review of Supplements to TIVDAK® License for Those Suffering from Advanced Cervical Cancer Relapse or Spread
Latest Hotspot
3 min read
FDA Fast-Tracks Review of Supplements to TIVDAK® License for Those Suffering from Advanced Cervical Cancer Relapse or Spread
15 January 2024
Pfizer and Genmab announced the FDA has accepted their supplemental application for TIVDAK.
Read →
Fate Therapeutics Announces Start of First Human Trial with FT825/ONO-8250 for HER2-positive Advanced Solid Tumors
Latest Hotspot
3 min read
Fate Therapeutics Announces Start of First Human Trial with FT825/ONO-8250 for HER2-positive Advanced Solid Tumors
15 January 2024
Fate Therapeutics Reveals Commencement of Initial Human Trial for FT825 / ONO-8250 in Individuals Suffering from HER2-positive Progressive Solid Cancers.
Read →
Exploring the Latest New Endocrine Therapy for ESR1 Mutation Breast Cancer by Shanghai Henlius Biotech: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest New Endocrine Therapy for ESR1 Mutation Breast Cancer by Shanghai Henlius Biotech: A Guide to Rapidly Accessing Transaction Insights
15 January 2024
Henlius Biotech and Sermonix Pharmaceuticals have formed a strategic alliance for the exclusive development, production, and commercialization of the investigational drug lasofoxifene in China.
Read →
Astellas Issues Progress Report on U.S. Regulatory Submission for Zolbetuximab Biological License Application
Latest Hotspot
3 min read
Astellas Issues Progress Report on U.S. Regulatory Submission for Zolbetuximab Biological License Application
15 January 2024
Astellas Pharma Inc. announced on Jan 4, 2024, the FDA issued a complete response to their zolbetuximab Biologics License Application.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.